Twitter

Link your Twitter Account to Market Wire News


When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.


Be alerted of any news about your stocks and see what other stocks are trending.



home / articles / ACIU - AC Immune to Host KOL Webinar on Amyloid Plaque PET Imaging in Alzheimer's Disease as a Surrogate of Clinical Efficacy on November 9 2023 | Benzinga


ACIU - AC Immune to Host KOL Webinar on Amyloid Plaque PET Imaging in Alzheimer's Disease as a Surrogate of Clinical Efficacy on November 9 2023 | Benzinga

  • AC Immune to Host KOL Webinar on Amyloid Plaque PET Imaging in Alzheimer's Disease as a Surrogate of Clinical Efficacy on November 9, 2023

    Lausanne, Switzerland, November 02, 2023 – AC Immune SA (NASDAQ:ACIU), a clinical-stage biopharmaceutical company pioneering precision medicine for neurodegenerative diseases, today announced that it will host a KOL webinar on amyloid plaque PET imaging in Alzheimer's Disease as a surrogate of clinical efficacy on Thursday, November 9, 2023 at 10:00am ET / 4:00pm CET. To register, click here.

    The event will feature Prof. Victor Villemagne, MD (University of Pittsburgh), who will discuss the heightened interest in amyloid plaque PET imaging and the methodology, mechanisms, and clinical implications of plaque lowering in light of recent successful trials.

    The AC Immune team will also highlight its anti-Abeta active immunotherapy candidate, ACI-24.060, currently being evaluated in the ongoing Phase 1b/2 ABATE study for the treatment of Alzheimer's disease. Initial amyloid-PET imaging analyses in Alzheimer's patients to assess amyloid plaque reduction after 6 months of treatment with ACI-24.060 in the ABATE trial are anticipated in the first half of 2024.

    A live question and answer session will follow the presentations.

    About Prof. Victor Villemagne, MD
    Prof. Victor Villemagne, MD graduated Cum Laude in 1983 from the Universidad Nacional de Buenos Aires, Argentina. He was awarded a Post-Doctoral Fellowship in Nuclear Medicine in 1984 and continued his post-graduate studies at the Division of Nuclear Medicine at The Johns Hopkins Medical Institutions. He subsequently furthered his molecular neuroimaging training at NIDA (NIH), and at the University of Pittsburgh.

    In 2003 he joined the Neurodegeneration group at the University of Melbourne, where he performed several preclinical and clinical studies of new tracers for amyloid and tau imaging, and in 2020, he joined the Dept. of ...

    Full story available on Benzinga.com

  • Stock Information

    Company Name: AC Immune SA
    Stock Symbol: ACIU
    Market: NASDAQ
    Website: acimmune.com

    Menu

    ACIU ACIU Quote ACIU Short ACIU News ACIU Articles ACIU Message Board
    Get ACIU Alerts

    News, Short Squeeze, Breakout and More Instantly...